Trade GeoVax Labs, Inc. - GOVX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0264 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023374% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001151% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.001 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.3018 |
| Open | 2.1918 |
| 1-Year Change | 584.51% |
| Day's Range | 2.1918 - 2.3618 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 20, 2024 | 2.2818 | 0.0100 | 0.44% | 2.2718 | 2.3618 | 2.1818 |
| Dec 19, 2024 | 2.3018 | 0.0400 | 1.77% | 2.2618 | 2.3718 | 2.2018 |
| Dec 18, 2024 | 2.2318 | -0.0300 | -1.33% | 2.2618 | 2.4318 | 2.2118 |
| Dec 17, 2024 | 2.2518 | -0.0200 | -0.88% | 2.2718 | 2.2918 | 2.1518 |
| Dec 16, 2024 | 2.2618 | -0.0800 | -3.42% | 2.3418 | 2.3718 | 2.2418 |
| Dec 13, 2024 | 2.3418 | 0.0100 | 0.43% | 2.3318 | 2.3618 | 2.2718 |
| Dec 12, 2024 | 2.3718 | -0.0200 | -0.84% | 2.3918 | 2.4818 | 2.3118 |
| Dec 11, 2024 | 2.4218 | 0.0000 | 0.00% | 2.4218 | 2.4518 | 2.3418 |
| Dec 10, 2024 | 2.4318 | -0.1400 | -5.44% | 2.5718 | 2.5818 | 2.3918 |
| Dec 9, 2024 | 2.5818 | 0.0400 | 1.57% | 2.5418 | 2.6618 | 2.4418 |
| Dec 6, 2024 | 2.5018 | 0.2900 | 13.11% | 2.2118 | 2.5118 | 2.2018 |
| Dec 5, 2024 | 2.1718 | -0.0500 | -2.25% | 2.2218 | 2.3018 | 2.1518 |
| Dec 4, 2024 | 2.2218 | -0.0900 | -3.89% | 2.3118 | 2.3618 | 2.2018 |
| Dec 3, 2024 | 2.3318 | -0.1600 | -6.42% | 2.4918 | 2.5118 | 2.3118 |
| Dec 2, 2024 | 2.5018 | -0.1600 | -6.01% | 2.6618 | 2.7518 | 2.4618 |
| Nov 29, 2024 | 2.6218 | -0.0800 | -2.96% | 2.7018 | 2.7418 | 2.6018 |
| Nov 27, 2024 | 2.6918 | 0.0100 | 0.37% | 2.6818 | 2.7418 | 2.6018 |
| Nov 26, 2024 | 2.6818 | -0.2800 | -9.45% | 2.9618 | 3.0018 | 2.6718 |
| Nov 25, 2024 | 2.9918 | 0.0400 | 1.36% | 2.9518 | 3.1318 | 2.8918 |
| Nov 22, 2024 | 2.9318 | 0.2400 | 8.92% | 2.6918 | 3.0318 | 2.6518 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
GeoVax Labs, Inc. Company profile
About Geovax Labs Inc
GeoVax Labs, Inc. is a clinical-stage biotechnology company. The Company is focused on developing human vaccines and immunotherapies against infectious diseases and cancer using its platforms. Its product pipeline includes ongoing human clinical trials for COVID-19 and head and neck cancer. The Company is developing a number of vaccines and immunotherapies for prevention or treatment of infectious diseases and cancers. The Company’s product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02, GEO-EM01, GEO-LM01 and GEO-MM02. Its research and development programs include preventive vaccines against Zika Virus, hemorrhagic fever viruses (Ebola, Sudan, Marburg, and Lassa) and malaria, as well as immunotherapies for multiple solid tumors. The Company’s wholly owned subsidiaries include GeoVax, Inc. and Immutak Oncology, Inc.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Geovax Labs Inc revenues decreased 79% to $386K. Net loss increased from $3M to $18.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase from $2.4M to $15.6M (expense), General and administrative increase of 63% to $3.6M (expense).
Equity composition
Common Stock $.001 Par, 04/11, 40M auth., 15,699,909 issd. Insiders control approx. 39.31%. IPO: NA. Private Placement: 1997, 4.4M shares @ $1. 9/06, Co. acq. by GeoVax, Inc. & name changed from Dauphin Technology, Inc. 04/10, 1-for-50 reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
1900 Lake Park Drive
Suite 380
SMYRNA
GEORGIA 30080
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com